載入中
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
一般交易時段
US$18.34
−US$0.32 · -1.71%
盤中時間採用ET。市場資料可能有所延遲。
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
日內區間
目前US$18.34
52週區間
目前US$18.34
盤中時間採用ET。市場資料可能有所延遲。
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
日內區間
目前US$18.34
52週區間
目前US$18.34
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7084.9萬 USD | 30.2萬 USD | 31.4萬 USD | 177.2萬 USD | 296.3萬 USD |
| 毛利 | 7084.9萬 USD | 30.2萬 USD | 31.4萬 USD | 177.2萬 USD | 296.3萬 USD |
| 研究與開發 | 3.39億 USD | 2.38億 USD | 1.6億 USD | 1.01億 USD | 5688.6萬 USD |
| 銷售、一般及管理費用 | 9531.5萬 USD | 6108.3萬 USD | 9499.9萬 USD | 3518.2萬 USD | 2580.5萬 USD |
| 營業費用 | 4.34億 USD | 2.99億 USD | 2.55億 USD | 1.36億 USD | 8269.1萬 USD |
| 利息收入 | 2739.9萬 USD | 3213.2萬 USD | 1856.3萬 USD | 491.6萬 USD | 31.8萬 USD |
| 利息支出 | 494.8萬 USD | 304.6萬 USD | 184.7萬 USD | 48.6萬 USD | 3000 USD |
| 折舊和攤銷 | 46萬 USD | 54萬 USD | 52.2萬 USD | 25.5萬 USD | 12萬 USD |
| 營業利益 | −3.63億 USD | −2.99億 USD | −2.54億 USD | −1.34億 USD | −7972.8萬 USD |
| 淨利 | −3.43億 USD | −2.7億 USD | −2.38億 USD | −1.3億 USD | −7941.3萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7755.61萬0.00%2.3兆 USD0.03%US$381.46-0.13%
iShares Russell 2000 ETFIWM4873.96萬0.06%787.4億 USD0.19%US$277.91-0.37%
State Street SPDR S&P Biotech ETFXBI4584.59萬0.46%98.74億 USD0.35%US$151.48-1.49%
Vanguard Extended Market ETFVXF2645.97萬0.03%954億 USD0.05%US$233.49-0.64%
Dimensional - US Small Cap ETFDFAS1284.77萬0.04%338.69億 USD0.31%US$78.23-0.15%
Vanguard Russell 2000 ETFVTWO1201.85萬0.07%180億 USD0.06%US$112.25-0.36%
Schwab U.S. Small-Cap ETFSCHA1099.52萬0.05%218.24億 USD0.03%US$32.6601-0.40%
iShares Micro-Cap ETFIWC591.06萬0.45%13.17億 USD0.60%US$181.82-0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
